{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T18:02:32Z","timestamp":1784397752701,"version":"3.55.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T00:00:00Z","timestamp":1784332800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T00:00:00Z","timestamp":1784332800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Spanish Society of Radiation Oncology"},{"name":"Janssen Cilag S.A."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04505-3","type":"journal-article","created":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T17:06:08Z","timestamp":1784394368000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Expert consensus recommendations for the management of biochemical recurrence in prostate cancer: a Delphi study across clinical scenarios"],"prefix":"10.1007","author":[{"given":"Fernando","family":"L\u00f3pez Campos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Cou\u00f1ago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Antonio","family":"Vallejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoni","family":"Vilaseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6348-8646","authenticated-orcid":false,"given":"Daniel","family":"P\u00e9rez Fentes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,18]]},"reference":[{"key":"4505_CR1","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.eururo.2022.11.002","volume":"83","author":"S Gillessen","year":"2022","unstructured":"Gillessen S, Bossi A, Davis ID, De Bono J, Fizazi K, James ND, et al. Management of patients with advanced prostate cancer. Part I: intermediate-\/high-risk and locally advanced disease, biochemical relapse, and side effects of hormonal treatment: report of the Advanced Prostate Cancer Consensus Conference 2022. Eur Urol. 2022;83:267\u201393. https:\/\/doi.org\/10.1016\/j.eururo.2022.11.002.","journal-title":"Eur Urol"},{"key":"4505_CR2","unstructured":"European Association of Urology. Prostate cancer [Internet]. [cited 2025 Feb 4]. Available from: https:\/\/uroweb.org\/guidelines\/prostate-cancer."},{"key":"4505_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13185561","volume":"13","author":"M Kawase","year":"2024","unstructured":"Kawase M, Nakane K, Iinuma K, Kawase K, Taniguchi T, Tomioka M, et al. Overall survival and cancer-specific mortality in patients with prostate cancer undergoing definitive therapies: a narrative review. J Clin Med. 2024;13:5561. https:\/\/doi.org\/10.3390\/jcm13185561.","journal-title":"J Clin Med"},{"issue":"3","key":"4505_CR4","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/s41391-024-00890-4","volume":"28","author":"A Matsukawa","year":"2025","unstructured":"Matsukawa A, Yanagisawa T, Fazekas T, Miszczyk M, Tsuboi I, Kardoust Parizi M, et al. Salvage therapies for biochemical recurrence after definitive local treatment: a systematic review, meta-analysis, and network meta-analysis. Prostate Cancer Prostatic Dis. 2025;28(3):610\u201322. https:\/\/doi.org\/10.1038\/s41391-024-00890-4.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"4505_CR5","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/JU.0000000000002757","volume":"208","author":"JA Eastham","year":"2022","unstructured":"Eastham JA, Auffenberg GB, Barocas DA, Chou R, Crispino T, Davis JW, et al. Clinically localized prostate cancer: AUA\/ASTRO guideline, part I: introduction, risk assessment, staging, and risk-based management. J Urol. 2022;208:10\u20138. https:\/\/doi.org\/10.1097\/JU.0000000000002757.","journal-title":"J Urol"},{"key":"4505_CR6","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.eururo.2024.09.017","volume":"87","author":"S Gillessen","year":"2024","unstructured":"Gillessen S, Turco F, Davis ID, Efstathiou JA, Fizazi K, James ND, et al. Management of patients with advanced prostate cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC). Eur Urol. 2024;87:157\u2013216. https:\/\/doi.org\/10.1016\/j.eururo.2024.09.017.","journal-title":"Eur Urol"},{"issue":"5","key":"4505_CR7","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJMoa1607529","volume":"376","author":"WU Shipley","year":"2017","unstructured":"Shipley WU, Seiferheld W, Lukka HR, Major PP, Heney NM, Grignon DJ, et al. Radiation with or without antiandrogen therapy in recurrent prostate cancer. N Engl J Med. 2017;376(5):417\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1607529.","journal-title":"N Engl J Med"},{"key":"4505_CR8","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1016\/S1470-2045(19)30486-3","volume":"20","author":"C Carrie","year":"2019","unstructured":"Carrie C, Magn\u00e9 N, Burban-Provost P, Sargos P, Latorzeff I, Lagrange J-L, et al. Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial. Lancet Oncol. 2019;20:1740\u20139. https:\/\/doi.org\/10.1016\/S1470-2045(19)30486-3.","journal-title":"Lancet Oncol"},{"key":"4505_CR9","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1016\/S0140-6736(21)01790-6","volume":"399","author":"A Pollack","year":"2022","unstructured":"Pollack A, Karrison TG, Balogh AG, Gomella LG, Low DA, Bruner DW, et al. The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology\/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial. Lancet. 2022;399:1886\u2013901. https:\/\/doi.org\/10.1016\/S0140-6736(21)01790-6.","journal-title":"Lancet"},{"key":"4505_CR10","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","volume":"389","author":"SJ Freedland","year":"2023","unstructured":"Freedland SJ, De Almeida Luz M, De Giorgi U, Gleave M, Gotto GT, Pieczonka CM, et al. Improved outcomes with enzalutamide in biochemically recurrent prostate cancer. N Engl J Med. 2023;389:1453\u201365. https:\/\/doi.org\/10.1056\/NEJMoa2303974.","journal-title":"N Engl J Med"},{"key":"4505_CR11","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000004228","author":"ND Shore","year":"2025","unstructured":"Shore ND, De Giorgi U, Freedland SJ. Enzalutamide in men with high-risk biochemically recurrent prostate cancer: rationale and treatment considerations from EMBARK. J Urol. 2025. https:\/\/doi.org\/10.1097\/JU.0000000000004228.","journal-title":"J Urol"},{"key":"4505_CR12","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1136\/bmj.311.7001.376","volume":"311","author":"J Jones","year":"1995","unstructured":"Jones J, Hunter D. Consensus methods for medical and health services research. BMJ. 1995;311:376\u201380.","journal-title":"BMJ"},{"key":"4505_CR13","volume-title":"The RAND\/UCLA appropriateness method user\u2019s manual","author":"RAND Corporation","year":"2001","unstructured":"RAND Corporation. The RAND\/UCLA appropriateness method user\u2019s manual. Santa Monica (CA): RAND; 2001."},{"key":"4505_CR14","unstructured":"European Medicines Agency. Xtandi EPAR product information [Internet]. [cited 2025 May 26]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xtandi-epar-product-information_en.pdf."},{"key":"4505_CR15","unstructured":"US Food and Drug Administration. XTANDI\u00ae (enzalutamide) prescribing information [Internet]. [cited 2025 May 26]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/203415s024,213674s012lbl.pdf."},{"key":"4505_CR16","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s11912-025-01647-5","volume":"27","author":"L O\u2019Loughlin","year":"2025","unstructured":"O\u2019Loughlin L, Abel ML, Madan RA, Einstein DJ. Defining the role for hormone therapy in biochemically recurrent prostate cancer: what counts as a win for patients? Curr Oncol Rep. 2025;27:247\u201357. https:\/\/doi.org\/10.1007\/s11912-025-01647-5.","journal-title":"Curr Oncol Rep"},{"key":"4505_CR17","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.eururo.2019.01.049","volume":"77","author":"M Perera","year":"2020","unstructured":"Perera M, Papa N, Roberts M, Williams M, Udovicich C, Vela I, et al. Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer\u2014updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. Eur Urol. 2020;77:403\u201317. https:\/\/doi.org\/10.1016\/j.eururo.2019.01.049.","journal-title":"Eur Urol"},{"key":"4505_CR18","doi-asserted-by":"publisher","first-page":"5091","DOI":"10.1200\/JCO.2023.41.16_suppl.5091","volume":"41","author":"WR Armstrong","year":"2023","unstructured":"Armstrong WR, Clark KJ, Smith CP, Thin P, Djaileb L, Benz MR, et al. PSMA PET findings in an \u201cEMBARK-like\u201d cohort of patients with high-risk non-metastatic hormone-sensitive prostate cancer: a single center post-hoc retrospective analysis. J Clin Oncol. 2023;41:5091. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.5091.","journal-title":"J Clin Oncol"},{"key":"4505_CR19","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1016\/S0140-6736(24)00548-8","volume":"403","author":"CC Parker","year":"2024","unstructured":"Parker CC, Clarke NW, Cook AD, Kynaston H, Catton CN, Cross WR, et al. Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial. Lancet. 2024;403:2405\u201315. https:\/\/doi.org\/10.1016\/S0140-6736(24)00548-8.","journal-title":"Lancet"},{"key":"4505_CR20","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/bju.16484","volume":"134","author":"C Gonz\u00e1lez\u2010San Segundo","year":"2024","unstructured":"Gonz\u00e1lez\u2010San Segundo C, L\u00f3pez Campos F, G\u00f3mez Iturriaga A, Rodr\u00edguez A, Olivera J, Duque\u2010Santana V, et al. A randomised trial of short\u2010 vs long\u2010term androgen deprivation with salvage radiotherapy for biochemical failure following radical prostatectomy: URONCOR 06\u201024. BJU Int. 2024;134:568\u201377. https:\/\/doi.org\/10.1111\/bju.16484.","journal-title":"BJU Int"},{"key":"4505_CR21","unstructured":"Instituto de Investigaci\u00f3n en Oncolog\u00eda Radioter\u00e1pica - Fundaci\u00f3n Espa\u00f1ola de Oncolog\u00eda Radioter\u00e1pica. Short Versus Long-term Androgen Deprivation Therapy Combined With Salvage Radiotherapy in Prostate Cancer Patients With Biochemical Recurrence After Prostatectomy: a Multicentre Phase III Randomised Controlled Trial [Internet]. ClinicalTrials.gov; 2023 Nov [cited 2025 May 26]. ClinicalTrials.gov trial registration number: NCT05781217. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05781217."},{"key":"4505_CR22","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","volume":"65","author":"M Roach","year":"2006","unstructured":"Roach M, Hanks G, Thames H, Schellhammer P, Shipley WU, Sokol GH, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65:965\u201374. https:\/\/doi.org\/10.1016\/j.ijrobp.2006.04.029.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4505_CR23","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.eururo.2020.11.010","volume":"80","author":"LF Valle","year":"2021","unstructured":"Valle LF, Lehrer EJ, Markovic D, Elashoff D, Levin-Epstein R, Karnes RJ, et al. A systematic review and meta-analysis of local salvage therapies after radiotherapy for prostate cancer (MASTER). Eur Urol. 2021;80:280\u201392. https:\/\/doi.org\/10.1016\/j.eururo.2020.11.010.","journal-title":"Eur Urol"},{"key":"4505_CR24","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.4143\/crt.2021.985","volume":"54","author":"SU Lee","year":"2022","unstructured":"Lee SU, Kim J-S, Kim YS, Cho J, Choi SH, Nam T-K, et al. Optimal definition of biochemical recurrence in patients who receive salvage radiotherapy following radical prostatectomy for prostate cancer. Cancer Res Treat. 2022;54:1191\u20139. https:\/\/doi.org\/10.4143\/crt.2021.985.","journal-title":"Cancer Res Treat"},{"key":"4505_CR25","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.prnil.2018.04.005","volume":"7","author":"M Miyake","year":"2019","unstructured":"Miyake M, Tanaka N, Asakawa I, Owari T, Hori S, Morizawa Y, et al. The impact of the definition of biochemical recurrence following salvage radiotherapy on outcomes and prognostication in patients with recurrent prostate cancer after radical prostatectomy: a comparative study of three definitions. Prostate Int. 2019;7:47\u201353. https:\/\/doi.org\/10.1016\/j.prnil.2018.04.005.","journal-title":"Prostate Int"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04505-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04505-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04505-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T17:06:09Z","timestamp":1784394369000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04505-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,18]]},"references-count":25,"alternative-id":["4505"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04505-3","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,18]]},"assertion":[{"value":"14 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Fernando L\u00f3pez Campos has received honoraria for consulting, advisory roles, and as a speaker from Janssen, Astellas, AstraZeneca, Bayer, and Casen Recordati. He has also received travel, accommodation, and related expenses from Janssen, Astellas, Bayer, and Casen Recordati. Felipe Cou\u00f1ago reports sponsored research from Janssen; consulting and advisory roles with Janssen and AstraZeneca; lectures and educational activities supported by Janssen, Roche Farma, AstraZeneca, Astellas, and Recordati; and travel, accommodation, and expenses covered by AstraZeneca, Astellas, Janssen, Roche Farma, Ipsen, Recordati, and Bayer. Antoni Vilaseca has received consulting honoraria from Johnson & Johnson, Astellas, Bayer, Recordati, Ipsen, and Accord. Juan Antonio Vallejo reports receiving speaker honoraria from Novartis, Johnson & Johnson, Astellas, Pfizer, and EISAI. Daniel P\u00e9rez Fentes reports receiving consulting fees from Astellas, Bayer, Johnson & Johnson and Recordati; honoraria for lectures, presentations, speaker bureaus, manuscript writing, or educational events from Astellas, Bayer, Johnson & Johnson and Recordati; support for attending meetings and\/or travel from Bayer, Johnson & Johnson and Recordati; and participation in Data Safety Monitoring Boards or Advisory Boards for Accord, Astellas, Bayer, Johnson & Johnson and Recordati.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This Delphi consensus study did not involve direct participation of patients or collection of personal health data; therefore, formal ethical approval and informed consent were not required.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}